Programmed death-1 (PD-1) promotes T cell tolerance. Despite therapeutically targeting this pathway for chronic infections and tumors, little is known about how different T cell subsets are affected during blockade. We examined PD-1/PD ligand 1 (PD-L1) regulation of self-antigen-specific CD4 and CD8 T cells in autoimmune-susceptible models. PD-L1 blockade increased insulin-specific effector CD4 T cells in type 1 diabetes. However, anergic islet-specific CD4 T cells were resistant to PD-L1 blockade. Additionally, PD-L1 was critical for induction, but not maintenance, of CD8 T cell intestinal tolerance. PD-L1 blockade enhanced functionality of effector T cells, whereas established tolerant or anergic T cells were not dependent on PD-1/PD-L1 signaling to remain unresponsive. This highlights the existence of Ag-experienced T cell subsets that do not rely on PD-1/PD-L1 regulation. These findings illustrate how positive treatment outcomes and autoimmunity development during PD-1/ PD-L1 inhibition are linked to the differentiation state of a T cell. The Journal of Immunology, 2015, 194: 3551-3555. T he inhibitory receptor programmed death-1 (PD-1) interacts with PD ligand 1 (PD-L1) to regulate T cell function and autoimmunity (1-5). Prolonged, elevated PD-1 and PD-L1 expression occurs during chronic infections and cancer and leads to T cell exhaustion (6). PD-1 blockade can reinvigorate exhausted T cells, providing enhanced antiviral and antitumor responses (7, 8) . These observations led to the development of PD-1 pathway blockers, which are anticipated to revolutionize cancer therapy.
Materials and Methods

Mice
Female mice were housed in specific-pathogen free facilities, and all experiments were Institutional Animal Care and Use Committee approved at the University of Minnesota. NOD mice were purchased from Taconic. OT-I, iFABP-OVA, B6.g7, NOD.PD-1
2/2
, NOD.PD-L1 2/2 , and NOD. BDC2.5 Thy1.1 mice were generated as described (10, 11) .
Lymphocyte transfer, isolation, and detection
Seven thousand five hundred NOD.BDC2.5.Thy1.1 + CD4 T cells from 4-to 6-wk-old donors were transferred into prediabetic NOD mice with or without CFSE labeling (10) . Five hundred thousand naive OT-I CD8 T cells isolated from spleen (SPL) and lymph node (LN) were transferred i.v. to adult iFABP-OVA mice (11) . Insulin-specific CD4 T cells were detected by double insB 10-23r3 :I-A g7 tetramer staining and enrichment (13) . Intraepithelial lymphocytes (IEL) and SPL were isolated as described (11) .
Flow cytometry
Surface staining was performed as described (13 
Histology
Islet inflammation was scored as follows: 0, no insulitis; 1, perinsulitis; 2, ,25% of the islet is infiltrated; 3, ,75% of the islet is infiltrated; 4, ,25% of the islet mass is intact.
Administration of Abs
Anti-PD-L1 (M1H6 or 10F.9G2), PD-1 (J43), rat IgG2a, rat IgG2b, or hamster IgG was injected i.p. (10) . For CD4 tolerance, mice received two to three doses (250 mg) as indicated in each figure, and 250 mg every other day for 10 d for T1D incidence. Glucose levels .250 mg/dl are diabetic. For CD8 tolerance induction, iFABP-OVA mice received 200 mg anti-PD-L1 i.p.
(clone 10F.9G2) on the day of transfer and day +3. For CD8 tolerance maintenance, mice received 200 mg anti-PD-L1 starting at day 30 and doses every third day for 15 d.
Cytokine assays
IFN-g was measured as described from BDC2.5 cells 4 h after 500 mg i.v. of acetylated P31 (1040-31) peptide (YVRPLWVRME) (Genemed Sythesis) or OT-I cells after 1 mg/ml SIINFEKL ex vivo for 4 h (New England Peptide) (10, 11) .
Statistical analysis
Unpaired two-tailed Student t tests or Mann-Whitney tests with a 95% CI were performed using Prism 5 software (GraphPad Software). A p value ,0.05 was considered statistically significant.
Results and Discussion
Loss of PD-1 or PD-L1 results in increased numbers of insulin-specific CD4 T cells in NOD mice
The PD-1/PD-L1 pathway is essential for tolerance and autoimmunity (1, 3, 14) . We investigated the impact of genetic loss of PD-1 on endogenous insulin-specific CD4 T cells in diabetes-susceptible NOD mice. Using an insB 10-23r3 :I-A g7 tetramer (13, 15) , we quantified insulin-specific CD4 T cells in the secondary lymphoid organs (SLO) and pancreas of NOD. PD-1 2/2 mice. We observed significantly more insB 10-23r3 :I-A g7 tetramer-binding cells (insulin-specific) in the pancreatic LN (pancLN) of prediabetic and diabetic NOD.PD-1 2/2 mice compared with WT control NOD (Fig. 1A) and PD-L1 2/2 mice, but not control HEL [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] :I-A g7 tetramer binding cells (Supplemental Fig. 1A, 1B) . There was not a significant change in the total number of CD4 T cells in PD-1 or PD-L1 knockout mice (Supplemental Fig. 1C ). The number of insulin-specific CD4 T cells did not differ in either SLO or pancreas of prediabetic NOD and NOD.PD-1 2/2 mice, but was significantly higher in diabetic NOD.PD-1 2/2 mice (Fig. 1A) . Histological analysis revealed that prediabetic NOD.PD-1 2/2 mice had more severe islet inflammation compared with age-matched nondiabetic NOD mice, and this increased with diabetes (Fig. 1B) . These results indicate that PD-1 is a central regulator of autoreactive CD4 T cells in autoimmune-prone mice.
PD-L1 blockade fails to induce autoimmunity in diabetes-resistant B6.g7 mice PD-1 loss is known to potentiate autoimmunity in susceptible mice (1); however, its role in regulating known self-antigenspecific T cells in genetically resistant hosts is unclear. We previously examined insulin-specific T cells in NOD and B6.g7 mice, because of the known genetic risk of MHC for T1D (16) . We reported that both strains contained insulin-specific CD4 T cells. Insulin-specific CD4 T cells became activated in the pancLN and infiltrated the pancreas in NOD mice, but remained naive in B6.g7 mice (13) . In this study, PD-1 + insulin-specific T cells are increased in the SLO of NOD mice compared with B6.g7 mice ( Fig. 2A, 2B ). In B6.g7 mice, the frequency of insulin-specific PD-1 + cells was low, consistent with a naive phenotype. Interestingly, in NOD mice, the highest frequency of PD-1 + cells was in the pancreas ( Fig. 2C ). This result supports the idea that pancreatic cells are susceptible to PD-1 inhibition, consistent with previous work (10, 17) .
Considering the differences in PD-1 expression, we next injected anti-PD-L1 to NOD and B6.g7 mice. NOD mice rapidly developed T1D ( Fig. 2D) (2) . However, despite the fact that B6.g7 mice carry the highest genetic risk factor for T1D (16) , anti-PD-L1 did not induce T1D (Fig. 2D) . We hypothesized that PD-L1 blockade in NOD mice, but not B6.g7 mice, would cause insulin-specific cells to increase due to PD-1 expression ( Fig. 2A, 2B ) (10) . In NOD mice, CD44
high insulinspecific CD4 T cells were increased in the SPL and pancLN following anti-PD-L1 ( Fig. 2E ) and in the pancreas following anti-PD-1 but not anti-B7-1 blockade (Supplemental Fig.  1D ). In B6.g7 mice, PD-L1 blockade failed to increase CD44 high cells in the SPL (Fig. 2E ), but, unexpectedly, resulted in a significant increase in the pancLN. However, insulinspecific CD4 T cells did not infiltrate the pancreas and did not cause T1D (Fig. 2E, 2D ). Islet histology was examined and anti-PD-L1 caused severe insulitis in NOD, but not in B6.g7 mice (Fig. 2F ).
Differential susceptibility of islet-reactive CD4 T cell subsets to PD-1 blockade
Our results demonstrated that anti-PD-L1 selectively increased Ag-experienced cells (Fig. 2) . However, there is notable heterogeneity within the Ag-experienced (CD44   high   Foxp3 2 ) compartment in pancLN of NOD mice with both effector and anergic cells (13) . These populations have been characterized based on expression of two surface proteins, folate receptor 4 (FR4) and CD73 (13, 18 
CD73
2 effector T cells (13, 18) . Using these markers we tested the impact of PD-1 signaling in light of our previous work demonstrating that anti-PD-L1 promoted the breakdown of tolerance by inducing the T cell stop signal (17) and reversing tolerance causing diabetes (4) .
To investigate the role of PD-1 regulation on anergic and effector T cell subsets, we used our recently characterized adoptive transfer model of diabetes. In this model, a low number of naive BDC2.5 TCR transgenic T cells specific for an islet Ag were transferred into prediabetic NOD mice to mimic the endogenous response (10) . Using this model, 70% of the BDC2.5 CD4 T cells develop an anergic phenotype and 30% become effector T cells in the pancLN (Supplemental Fig. 1E ). Not surprisingly, these subsets differ in their proliferative capacity, with anergic subsets dividing less than effector T cells (Fig. 3A) . Interestingly, PD-1 levels are very similar on anergic and effector T cells (Supplemental Fig. 1H, 1I) . We tested whether anti-PD-L1 altered the frequency of anergic or effector T cell subsets. Anti-PD-L1 decreased the frequency of anergic cells (Supplemental Fig. 1E, 1F) . However, the decrease was not due to cell loss, but rather to a 3-fold expansion of effector T cells (Supplemental Fig. 1G ). We next measured the effect of PD-L1 blockade on anergic cells and predicted these cells would be reinvigorated, given our previous findings with Ag-coupled cell tolerance (4). Contrary to prediction, anergic cells were blunted in their ability to produce IFN-g. We measured a significant increase in IFN-g production by effector T cells with anti-PD-L1 (Fig. 3B-D) . The mean frequency of IFN-g + anergic cells rose from 16.9 to 25.6% after anti-PD-L1 but remained lower than effector cells with and without PD-L1 blockade (43.7 and 58.4%, respectively) (Fig. 3C) . If anti-PD-L1 had released the anergic CD4 T cells, we would have observed equal levels of IFN-g, but this was not the case, indicating there is a subset of anergic CD4 T cells that are not reinvigorated by PD-L1 blockade. Even though the percentage of IFN-g + cells changed in the anergic population, the amount of produced IFN-g did not increase above baseline following anti-PD-L1 (Fig. 3D ). Anergic cells made 1.5-fold less IFN-g than did effector cells in control animals and 2-fold less than did effectors after anti-PD-L1 on a per cell basis (Fig. 3D) . Lastly, we measured CXCR3 expression on anergic and effector cells and determined CXCR3 was higher on CD4 effector cells compared with anergic cells, which could mechanistically explain a differential ability of these cells to traffic to sites of inflammation during autoimmunity (Supplemental Fig. 1J ). We have previously reported that CXCR3 expression increased following PD-L1 blockade and did not detect any CXCR3 + anergic cells in the pancreas (13) . This is consistent with the idea that anergic cells remain in the periphery and the effector cells traffic to the pancreas to cause T1D (13) . Taken together, our results suggest that PD-L1 blockade has the greatest impact on the effector T cell subset allowing enhanced proliferation and IFN-g production over anergic cells (Fig. 3D) . This is consistent with reports of PD-L1-mediated restoration of exhausted CD8 subsets (19) .
The differences between anergic and effector cells may be explained by two potential mechanisms. Previous reports implicate that other inhibitory receptors such as CTLA-4, LAG-3, 2B4, and TIM-3 may contribute to the establishment of T cell exhaustion or anergy via nonredundant signaling pathways (20) . Alternatively, incomplete TCR stimulation (TCR stimulation without costimulation) leading to a calcium influx-mediated altered gene expression program that includes upregulation of several E3 ubiquitin ligases and T cell anergy may explain the differences between anergic and effector cells (21) . What was not known from these studies was whether PD-L1 blockade can reverse this state of anergy and allow for T cell reinvigoration. We conclude from our data that PD-L1 blockade results in differential responsiveness for anergic and effector CD4 T cells.
PD-L1 blockade enhances effector functions of self-antigen-specific CD8 T cells during the induction, but not the maintenance, of tolerance
We next asked whether there was differential PD-L1 dependence of self-antigen-specific CD8 T cells. We transferred naive OVA-specific OT-I CD8 T cells to iFABP-OVA mice expressing OVA as an intestinal self-antigen (11, 12) . This system eliminates recent thymic emigrants and synchronizes Ag encounter. Importantly, we evaluated both the induction and maintenance of CD8 T cell tolerance, which has previously been difficult, as deletion of transferred T cells is common. This model overcomes this barrier and results in long-term maintenance of self-specific CD8 T cells, indicating that T cell deletion is not necessarily the outcome of tolerogenic interactions (22) .
Previous work using this model suggested a role for PD-1/ PD-L1 in the initiation of mucosal CD8 T cell tolerance (23) . In the present study, when PD-L1 was blocked early, tolerance induction was prevented. Anti-PD-L1 caused an increase in the frequency and number of OT-I T cells in the SPL and small intestine (IEL) of iFABP-OVA mice and enhanced IFN-g production from OT-I IEL and granzyme B (Fig. 4A, 4B, Supplemental Fig. 2A, 2B) . As a result of PD-L1 blockade, mice died of severe intestinal inflammation by day 10 (data not shown). OT-I cells examined 30 d after transfer had characteristics of anergic T cells: they were Ag experienced, but did not exhibit effector functions and could be found in Ag-rich locations, including the IEL (Fig. 4 , Supplemental Fig. 2A, 2B ) (11) . Similar to BDC2.5 T cells, CXCR3 expression was increased on effector OT-I CD8 T cells compared with anergic cells (Supplemental Fig. 2C) . Surprisingly, once anergy was established, PD-L1 blockade did not increase OT-I cell numbers or restore effector functions (Fig. 4) . This resistance to treatment was not due to downregulation of the receptor PD-1, because these cells retain expression (Supplemental Fig. 2D ). Importantly, anti- PD-L1 during tolerance maintenance did not promote intestinal pathology (data not shown). These data demonstrate critical differences in the temporal requirement for PD-L1 in CD8 T cell tolerance.
The inhibitory receptor PD-1 has long been considered a central mediator of peripheral tolerance, facilitating T cell inhibition and preventing effector function. In this study, however, we report the unexpected finding that the inhibitory effects of PD-1/PD-L1 signaling and subsequent blockade act on specific subsets of CD4 and CD8 T cells. We found that PD-1/PD-L1 blockade preferentially acts to restore or potentiate the function of effector cells, rather than broadly reversing tolerance in all T cell subsets. These results suggest that effector T cells are restrained via PD-1 inhibitory signals, whereas anergic T cells are not released through PD-L1 blockade alone. These data have important implications for patients receiving PD-1 pathway inhibitors for treatment of cancer or chronic infections, as it suggests that the functional state of T cells will impact patient outcomes. This highlights the importance of autoreactive T cell activation status as an indicator for study exclusion criteria. Additionally, our results indicated that PD-L1 blockade alone did not reverse tolerance of selfreactive anergic T cells to cause autoimmunity. Better clinical efficacy of PD-1 pathway inhibitors may be possible by combining blockade with effective therapeutic vaccination to reverse the tolerant or exhausted state of tumor-or microbe-specific T cells and produce synergistic effects (24) . Understanding how PD-1 blockade impacts autoreactive T cells in hosts with varying autoimmune susceptibility is critically important as PD-1 inhibitor use moves forward in the clinic (25, 26) .
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